Breaking News Instant updates and real-time market news.

HUM

Humana

$268.83

1.28 (0.48%)

, WMT

Walmart

$88.97

1.2 (1.37%)

07:59
03/30/18
03/30
07:59
03/30/18
07:59

Walmart acquiring Humana not likely at this point, Bloomberg reports

Walmart (WMT) is in talks with Humana (HUM) for a closer partnership to provide health care to consumers at home and prevent illness, Zachary Tracer and Ed Hammond of Bloomberg reported late last night, citing a person familiar with the matter. Their report follows the Wall Street Journal's, which said last night that Walmart was in early talks to acquire Humana. However, a person familiar with the matter told Bloomberg that while Walmart and Humana have explored a wide range of options including a merger, an outright combination isn't likely at this point. Following the Journal's report, shares of Humana jumped 11% in afterhours trading, or $28.67, to $297.50. Walmart dropped 1%, or $1.06, to $88.97. Other health insurers, including Anthem (ANTM), UnitedHealth Group (UNH), Cigna (CI), Centene (CNC) and Aetna (AET), also saw their stocks rally following the Journal's report. Reference Link

HUM

Humana

$268.83

1.28 (0.48%)

WMT

Walmart

$88.97

1.2 (1.37%)

ANTM

Anthem

$219.70

-1.78 (-0.80%)

UNH

UnitedHealth

$214.00

-4.5 (-2.06%)

CI

Cigna

$167.74

-0.58 (-0.34%)

CNC

Centene

$106.87

6.52 (6.50%)

AET

Acquired by CVS

$169.00

-0.43 (-0.25%)

  • 03

    Apr

  • 10

    Apr

  • 16

    Apr

  • 17

    Apr

  • 24

    Apr

  • 30

    May

  • 30

    May

  • 01

    Jun

HUM Humana
$268.83

1.28 (0.48%)

02/08/18
FBCO
02/08/18
UPGRADE
FBCO
Outperform
Humana upgraded to Outperform from Neutral at Credit Suisse
02/08/18
OPCO
02/08/18
NO CHANGE
Target $305
OPCO
Outperform
Humana price target raised to $305 from $275 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Humana to $305 from $275 after the company reported quarterly results. The analyst reiterates an Outperform rating on the shares.
02/08/18
02/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wynn Resorts (WYNN) upgraded to Positive from Neutral at Susquehanna with analyst Rachael Rothman saying the resignation of Steve Wynn removes an overhang. 2. Molson Coors (TAP) upgraded to Hold from Sell at Berenberg with analyst Javier Gonzalez Lastra saying he sees limited downside from the current share price and thinks greater cost savings could be a near-term upside catalyst. 3. Humana (HUM) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying after ceding market share for "several years," Humana should return to above market individual Medicare Advantage enrollment growth in 2019 as it benefits from a favorable rate update and tax reform. 4. Anadarko (APC) upgraded to Outperform from Neutral at Macquarie with analyst Paul Grigel saying he sees sustainable upside into 2018 due to continued strong growth in US production, infrastructure and its advantage in the DJ Basin. 5. Just Energy (JE) was upgraded to Outperformer from Neutral at CIBC and to Buy from Hold at Canaccord. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/18
FBCO
02/08/18
UPGRADE
Target $306
FBCO
Outperform
Credit Suisse upgrades Humana ahead of 2019 enrollment growth
Credit Suisse analyst A.J. Rice upgraded Humana to Outperform and raised his price target for the shares to $306 from $259. After ceding market share for "several years," Humana should return to above market individual Medicare Advantage enrollment growth in 2019 as it benefits from a favorable rate update and tax reform, Rice tells investors in a research note. He sees "several drivers" that support his core operating earnings growth assumption of 12% in 2018.
WMT Walmart
$88.97

1.2 (1.37%)

03/02/18
OPCO
03/02/18
DOWNGRADE
Target $93
OPCO
Perform
Oppenheimer 'no longer sees the case' for Walmart outperformance
Oppenheimer analysts Rupesh Parikh and Brian Nagel downgraded Walmart to Perform from Outperform on increasing concerns of dwindling e-commerce sales expansion and a more muted EPS growth view. Though the analysts, who cut their price target on shares to $93 from $110, remain "upbeat" on the retailer's strategic direction, they no longer see the case for Walmart outperformance and are "increasingly concerned" that the valuation at which shares trade could prove capped.
02/26/18
02/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Walmart (WMT) initiated with a Neutral and Target (TGT) initiated with an Outperform at Credit Suisse. 2. Hudson (HUD) initiated with a Buy at Goldman Sachs, a Buy at UBS, an Equal Weight at Morgan Stanley and an Outperform at Credit Suisse. 3. VICI Properties (VICI) initiated with a Buy at Stifel, a Neutral at Goldman Sachs and an Equal Weight at Barclays. 4. Sage Therapeutics (SAGE) initiated with an Overweight at Morgan Stanley. 5. Sol-Gel Technologies (SLGL) initiated with a Buy at Jefferies and an Outperform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/02/18
03/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Walmart (WMT) downgraded to Perform from Outperform at Oppenheimer by analysts Rupesh Parikh and Brian Nagel, who said that while they remain "upbeat" on the retailer's strategic direction, they no longer see the case for Walmart outperformance and are "increasingly concerned" that the valuation at which shares trade could prove capped. 2. VMware (VMW) downgraded to Hold from Buy at Stifel by analyst Brad Reback, who sees "too much uncertainty" as parent Dell Technologies (DVMT) evaluates "potential business opportunities." He believes, however, that VMware continues to execute well following its "strong" Q4 results. 3. Ruth's Hospitality (RUTH) downgraded to Hold from Buy at Deutsche Bank by analyst Brett Levy, who said the company's progress and upside are largely priced in given the company's premium multiple, Levy tells investors in a research note. The analyst this morning also upgraded both Bloomin' Brands (BLMN) and Del Frisco's (DFRG) to Buy. 4. Opko Health (OPK) downgraded to Underweight from Neutral at JPMorgan by analyst Eric Joseph, who believes the company's Q4 miss raises "significant doubts" for the core diagnostics/ BRL business. He believes the stock will continue to see pressure going forward. 5. Pure Storage (PSTG) downgraded to Neutral from Positive at Susquehanna by analyst Mehdi Hosseini, who cited the lack of visibility, particularly around FlashBlade, to raise estimates from current levels, which would be necessary for the next leg of appreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/02/18
OPCO
03/02/18
DOWNGRADE
OPCO
Perform
Walmart downgraded to Perform from Outperform at Oppenheimer
ANTM Anthem
$219.70

-1.78 (-0.80%)

03/09/18
LEER
03/09/18
NO CHANGE
Target $335
LEER
Outperform
Leerink sees favorable risk/reward on Anthem, ups target to $335
Leerink analyst Ana Gupte raised her price target for Anthem to $335 from $325 citing increased conviction on the company's favorable risk/reward in the managed care organization group. Near-term fears of flu in Q1 and accelerating cost trend are overblown, Gupte tells investors in a research note. After hosting meetings with management, the analyst reiterates her above consensus estimates on Anthem and Outperform rating.
03/08/18
JEFF
03/08/18
NO CHANGE
Target $248
JEFF
Buy
Cigna selloff today a buying opportunity, says Jefferies
Jefferies analyst David Windley recommends using the selloff today in shares of Cigna (CI) as a buying opportunity. The analyst estimates low- to mid-teens earnings accretion through 2021 from the Express Scripts (ESRX) acquisition, essentially matching management's target. Windley believes Cigna's customer retention guidance caused some confusion. He notes that management's guidance assumes Anthem (ANTM) is out in all years. The analyst keeps a Buy rating on Cigna with a $248 price target.
03/13/18
BERN
03/13/18
INITIATION
Target $194
BERN
Market Perform
Cigna initiated with a Market Perform at Bernstein
Bernstein analyst Lance Wilkes initiated Cigna (CI) with a Market Perform rating and $195 price target following Cigna's announcement that it will buy Express Scripts (ESRX) for $67B. Wilkes views the deal as a bet that change comes more slowly to healthcare, and that financial returns from this deal will fund future strategic acquisitions for Cigna. In a research note to investors, Wilkes said he believes disruption is coming more quickly, in PBM and pharmacy and in the shift to value, and is "skeptical" of this move by Cigna. The analyst expects earnings growth to slow for Cigna driven by its employer focus, lack of scale and already best in class margins, and added that he has a "negative" outlook for Express Scripts, expecting declining gross margins as they lose Anthem (ANTM) and client pricing pressure as focus increases on drug costs.
03/08/18
LEHM
03/08/18
INITIATION
Target $270
LEHM
Overweight
Anthem initiated with an Overweight at Barclays
Barclays analyst Steve Valiquette started Anthem with an Overweight rating and $270 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
UNH UnitedHealth
$214.00

-4.5 (-2.06%)

03/12/18
WBLR
03/12/18
NO CHANGE
WBLR
Outperform
Insulet announced coverage win with UnitedHealth, says William Blair
Insulet (PODD) on Friday announced it had established a new contract with UnitedHealthcare (UNH), which would provide its patients with in-network, durable medical equipment coverage for Omnipod beginning April 1, William Blair analyst Margaret Kaczor tells investors in a research note. This is another coverage win for Insulet as UnitedHealth represents almost 50M lives in the United States, the analyst adds. She notes Insulet has had limited access to historically a Medtronic (MDT) has been UnitedHealth's preferred, in-network DME insulin pump provider since mid-2016. Kaczor views the announcement as "another improvement in patient access to Omnipod." She thinks Insulet "continues to fire on all cylinders" and keeps an Outperform rating on the shares.
03/13/18
ADAM
03/13/18
NO CHANGE
Target $90
ADAM
Buy
Insulet improved market access reinforces growth opportunity, says Canaccord
Canaccord analyst Kyle Rose noted UnitedHealth (UNH) has agreed to cover the Insulet (PODD) OmniPod for its 70M covered lives. The announcement provides a meaningful growth opportunity for 2018 and beyond. The increased market access reinforces his conviction that Insulet remains in the early stages of a transformative period of meaningful market share gains. Rose reiterated his Buy rating and raised his price target to $90 from $88 on Insulet shares.
03/15/18
JEFF
03/15/18
NO CHANGE
Target $46
JEFF
Buy
Envision selloff yesterday a buying opportunity, says Jefferies
Jefferies analyst Brian Tanquilut views yesterday's selloff in shares of Envision Healthcare (EVHC) following news that UnitedHealth (UNH) dropped out of the bidding process for the company's ASC segment as an overreaction. The analyst continues to believe that the board's strategic review will result in a sale of Envision. He believes yesterday's pullback provides a "compelling entry opportunity." His leveraged buyout analysis says a $50-plus per share takeout is possible. Tanquilut keeps a Buy rating on Envision Healthcare with a $46 price target.
03/19/18
ADAM
03/19/18
NO CHANGE
Target $115
ADAM
Buy
UnitedHealth contract a potential NT catalyst for Quest, says Canaccord
Canaccord analyst Mark Massaro raised his price target on Quest Diagnostics (DGX) to $115 from $113 following investor meetings with Shawn Bevec, Quest's Executive Director of IR. Massaro, who reiterated a Buy rating, views Quest as an underappreciated large cap "cash cow" well positioned to consolidate labs, particularly in the $48B hospital lab market, where he says it has a "competitive edge" over LabCorp (LH). Additionally, Massaro said the fate of the UnitedHealth (UNH) contract, an exclusive to LabCorp but is set to expire at the end of the year, remains a potential near-term positive catalyst for Quest, noting that Quest is in "active dialogue" with UnitedHealth executives at the highest levels" and at Optum. Though UnitedHealth could renew the deal with LabCorp, Massaro believes it is likely that the contract will open up to both LapCorp and Quest.
CI Cigna
$167.74

-0.58 (-0.34%)

03/15/18
DBAB
03/15/18
NO CHANGE
Target $236
DBAB
Buy
Cigna shares look oversold with or without deal, says Deutsche Bank
Cigna (CI) shares are down 26% from the January $226 high and 14% since the Express Scripts (ESRX) deal was announced on March 8, Deutsche Bank analyst Chris Rigg tells investors in a research note. The analyst estimates pro forma 2021 earnings per share of $21.18 for Cigna and Express Scripts. As such, he sees "ample conservatism" in management's 2021 EPS target range of $20-$21. With or without the deal, Cigna shares look oversold, Rigg contends. He keeps a Buy rating on Cigna with a $236 price target.
03/12/18
LEER
03/12/18
NO CHANGE
LEER
Diplomat Pharmacy may be next takeover target, says Leerink
Leerink analyst David Larsen believes Diplomat Pharmacy (DPLO) could be the next takeover target following last week's buyout of Express Scripts (ESRX). A managed care plan or large pharmacy chain may find Diplomat's portfolio compelling, Larsen told investors earlier in a research note. He believes the rally post Cigna's (CI) acquisition of Express Scripts reflects a higher likelihood of a takeover, but that "significant upside" potential remains in Diplomat shares.
03/12/18
03/12/18
UPGRADE
Target $80

Market Perform
Express Scripts upgraded to Market Perform at Bernstein
As previously reported, Bernstein analyst Lance Wilkes upgraded Express Scripts (ESRX) to Market Perform from Underperform, stating that while he continues to be bearish on the underlying business, he views the deal to be acquired by Cigna (CI) for approximately $91 per share as a "very positive outcome." He would expect regulatory approval based upon lack of overlap, though Wilkes thinks it will likely be an extended regulatory process.
CNC Centene
$106.87

6.52 (6.50%)

03/26/18
BMOC
03/26/18
NO CHANGE
BMOC
Outperform
Centene weakness on NY worries a buying opportunity, says BMO Capital
BMO Capital analyst Matthew Borsch said he would not overreact to a Politico report that Centene's pending acquisition of Fidelis health plan is in jeopardy due to a fight between the Archdiocese of New York and Governor Cuomo. The dispute may impact the deal timing, but both parties have more to gain than lose and he suspects the deal is still substantially more likely than not to get done, Borsch tells investors. The analyst, who said he would be a buyer on any weakness, keeps an Outperform rating on Centene, which he identifies as his favorite name in Managed Care.
02/21/18
PIPR
02/21/18
NO CHANGE
PIPR
Piper sees 'ideal time' to buy Medicaid Managed Care Organizations
Now is an "ideal time" to step in and buy Medicaid Managed Care Organizations Centene (CNC), Molina Healthcare (MOH) and WellCare (WCG), Piper Jaffray analyst Sarah James tells investors in a research note. The stocks are down 12% over the last few weeks due to a combination of the flu and various reform/waiver concerns, the analyst points out. She does not view these as material and says "this is when you double down." Centene is James' top pick.
02/13/18
LEER
02/13/18
NO CHANGE
Target $100
LEER
Market Perform
Centene price target raised to $100 from $90 at Leerink
Leerink analyst Ana Gupte raised her price target for Centene to $100 form $90 saying the Q4 report was "good" and 2018 guidance raise for tax tailwinds was above expectations. The analyst reiterates a Market Perform rating on the shares.
02/07/18
OPCO
02/07/18
NO CHANGE
Target $130
OPCO
Outperform
Centene price target raised to $130 from $122 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Centene to $130 from $122, citing Q4 Beat and raised 2018 outlook on exchanges and Tax-Reform. The analyst reiterates an Outperform rating on the shares.
AET Acquired by CVS
$169.00

-0.43 (-0.25%)

02/01/18
02/01/18
DOWNGRADE
Target $69

Underperform
Express Scripts downgraded to Underperform at Bernstein
As previously reported, Bernstein analyst Lance Wilkes downgraded Express Scripts to Underperform from Market Perform, with a $69 price target, as he believes tax reform is fully price in and his original concerns on the standalone PBM model remain. Further, the analyst sees additional risks from a potential CVS (CVS)/Aetna (AET) merger and Amazon (AMZN) threats.
01/31/18
FBCO
01/31/18
NO CHANGE
Target $208
FBCO
Neutral
Aetna price target raised to $208 from $200 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Aetna to $208 from $200, citing on track operationally. However, the analyst is cautious on sustainability of tax benefit. He reiterates a Neutral rating on the shares.
01/31/18
RBCM
01/31/18
UPGRADE
Target $98
RBCM
Outperform
Express Scripts upgraded to Outperform at RBC Capital
As reported earlier, RBC Capital analyst George Hill upgraded Express Scripts (ESRX) to Outperform and raised his price target to $98 from $68. Hill cites the "recent sharp pullback on Amazon's (AMZN) healthcare entry" de-risking the stock, while also pointing to the trend of vertical integration as seen in the CVS (CVS)-Aetna (AET) deal. The analyst believes Express Scripts could also become an attractive M&A target as "one of the few remaining assets at scale".
01/31/18
PIPR
01/31/18
NO CHANGE
Target $212
PIPR
Overweight
Piper sees buying opportunity in Aetna after yesterday's pullback
Piper Jaffray analyst Sarah James sees a buying opportunity in Aetna (AET) following yesterday's 3% pullback on the Amazon (AMZN), Berkshire (BRK.A) and JPMorgan (JPM) news. The company yesterday morning posted a solid earnings beat driven by strong cost trend management in the government and commercial businesses, James tells investors in a research note. She raised her price target for Aetna shares to $212 from $207 and keeps an Overweight rating on the name. CVS Health's (CVS) takeout offer now values the shares at $212, up from $207 previously, based on 0.8378 shares of CVS stock plus $145 per share in cash, James points out. The analyst sees a "win-win" setup for the stock based on the deal going through or the company remaining standalone.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56
Hot Stocks
Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA »

Merck KGaA, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    May

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48
Hot Stocks
Merck presents results from Phase 3 KEYNOTE-426 study »

Merck (MRK) announced…

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Apr

  • 18

    May

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

12:42
02/17/19
02/17
12:42
02/17/19
12:42
Hot Stocks
Aveo Pharmaceuticals presents TIVO-3 trial topline results »

Aveo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDM

Aradigm

$0.00

(0.00%)

12:34
02/17/19
02/17
12:34
02/17/19
12:34
Hot Stocks
Aradigm announces plans for reorganization under Chapter 11 »

Aradigm has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.